The Public M&A and Life Sciences teams advised Blueprint Medicines Corporation on the completion of its acquisition by Sanofi (NASDAQ: SNY).
The definitive agreement between Blueprint and Sanofi was announced on June 2, 2025.
Blueprint Medicines Corporation is a global, fully integrated biopharmaceutical company that invents life-changing medicines. They seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Their approach begins by targeting the root causes of disease, using deep scientific knowledge in their core focus areas and drug discovery expertise across multiple therapeutic modalities. They have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with SM in the US and Europe. Leveraging their established research, development, and commercial capability and infrastructure, they aim to significantly scale their impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases and solid tumors.
The Goodwin team was led by Stuart Cable, Lisa Haddad, Kingsley Taft, Danielle Lauzon, Sarah Solomon, Sarah Bock and James Ding.
For additional details on the acquisition, please read the press release.